Global Gene Therapy For Parkinson's Disease Market Projected to Grow at 26.1% CAGR, Reaching $1.62 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Gene Therapy For Parkinson's Disease Industry Market Size Be by 2025?
The market size for the gene therapy for Parkinson's disease has seen exponential growth lately. The market which stood at $0.51 billion in 2024 is expected to balloon to $0.64 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 26.5%. This considerable growth in the historic period can be connected to factors such as increasing cases of Parkinson's disease, a surge in demand for personalized treatments, heightened awareness about gene therapy, an expanded network of clinical trials, and a rise in funding towards research on neurodegenerative diseases.

What's the Long-Term Growth Forecast for the Gene Therapy For Parkinson's Disease Market Size Through 2029?
The market size for gene therapy in the treatment of Parkinson's disease is predicted to undergo substantial growth in the upcoming years. It is set to reach $1.62 billion in 2029, experiencing a compound annual growth rate (CAGR) of 26.1%. The surge in the projected period can be credited to the rising acceptance of viral vector-founded therapies, enhanced investment in gene therapy start-ups, increasing governmental aid for treatments of rare diseases, broadening of research collaborations, and the development of healthcare infrastructure in nascent markets. Key trends during the projection period encompass breakthroughs in viral delivery systems technology, innovations in neurotrophic factor therapies, creation of targeted gene-editing structures, augmented research and development investments, and improvements in precision medicine methods.

View the full report here:
https://www.thebusinessresearchcompany.com/report/gene-therapy-for-parkinsons-disease-global-market-report

What Are the Key Growth Drivers Fueling the Gene Therapy For Parkinson's Disease Market Expansion?
The burgeoning fascination with personalized medicine is anticipated to catalyze the gene therapy for Parkinson's disease market's expansion. Personalized medicine entails a medical approach that customizes therapy and prevention plans according to an individual's genetic composition, lifestyle, and environment. The escalation in interest for personalized medicine spawns from the increasing demand for targeted therapies that enhance treatment efficacy and reduce adverse side effects. Within personalized medicine, gene therapy for Parkinson's disease is utilized to provide tailor-made genetic alterations that rejuvenate dopamine functionality and tackle specific disease mechanisms of each patient. For example, the Personalized Medicine Coalition, a non-profit establishment based in the US, revealed in February 2024, that the US Food and Drug Administration (FDA) had sanctioned 16 novel personalized cures for rare disease patients in 2023, which marked a significant rise from the six approvals in 2022. Hence, the surging interest in personalized medicine is propelling the growth of the Parkinson's disease gene therapy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28231&type=smp

What Are the Key Trends Driving Gene Therapy For Parkinson's Disease Market Growth?
Leading businesses are active in the Parkinson's disease gene therapy market, with a strategic focus on the development of more accurate therapies such as regenerative medicine advanced therapy. This approach aims to improve neuron survival, restore the functionality of dopamine, and grant enduring disease-modifying benefits to Parkinson's patients. The term regenerative medicine advanced therapy (RMAT) is defined as a unique United States Food and Drug Administration (FDA) designation applied to regenerative medicine products like cell therapies, gene therapies, and tissue-engineered products aimed at treating, modifying, reversing or curing severe or potentially fatal diseases. An example of this is when Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy organisation based in the US, launched AB-1005 - an experimental AAV2-GDNF gene therapy which received the FDA's regenerative medicine advanced therapy (RMAT) designation, in February 2025. This particular designation, assigned in order to accelerate the development and review of therapies showing promise, was based on data provided by AskBio. This included clinical evidence from a Phase Ib open-label, uncontrolled trial which suggested that AB-1005 could slow disease progression and enhance motor functionality in Parkinson's patients.

How Is the Gene Therapy For Parkinson's Disease Market Segmented?
The gene therapy for parkinson's disease market covered in this report is segmented as

1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy
2) By Vector Type: Viral Vectors, Non-Viral Vectors
3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes
4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegment:
1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors
2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28231&type=smp

Which Companies Are Leading the Charge in Gene Therapy For Parkinson's Disease Market Innovation?
Major companies operating in the gene therapy for parkinson's disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.

Which Regions Are Leading the Global Gene Therapy For Parkinson's Disease Market in Revenue?
North America was the largest region in the gene therapy for parkinson's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gene therapy for parkinson's disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28231

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.